Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
Scientific Reports|June 20, 2020
The influence of hypoxia and energy depletion on the response of endothelial cells to the vascular disrupting agent combretastatin A-4-phosphateToby Holmes, Andrew W Brown, Marie Suggitt, et al.
International Journal of Cancer|December 15, 2010
Vascular effects dominate solid tumor response to treatment with combretastatin A-4-phosphateSarah Jane Lunt, Simon Akerman, Sally A Hill, et al.
Anticancer Research|August 21, 2003
The vascular targeting agent combretastatin A-4-phosphate induces neutrophil recruitment to endothelial cells in vitroAndrew C Brooks, Chryso Kanthou, Ian H Cook, et al.
BMC Cancer|December 13, 2006
Anti-vascular agent Combretastatin A-4-P modulates hypoxia inducible factor-1 and gene expressionGabi U Dachs, Andrew J Steele, Claudia Coralli, et al.
Cancer Research|April 6, 2017
Differential Expression of VEGFA Isoforms Regulates Metastasis and Response to Anti-VEGFA Therapy in SarcomaWilliam R English, Sarah Jane Lunt, Matthew Fisher, et al.
Plos One|August 15, 2014
Tumour cells expressing single VEGF isoforms display distinct growth, survival and migration characteristicsChryso Kanthou, Gabi U Dachs, Diane V Lefley, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 13, 2010
Systemic antiangiogenic activity of cationic poly-L-lysine dendrimer delays tumor growthKhuloud T Al-Jamal, Wafa' T Al-Jamal, Simon Akerman, et al.
International Journal of Cancer|May 29, 2013
Influence of soluble or matrix-bound isoforms of vascular endothelial growth factor-A on tumor response to vascular-targeted strategiesSimon Akerman, Matthew Fisher, Rachel A Daniel, et al.
Cancer Research|April 3, 2008
Blood vessel maturation and response to vascular-disrupting therapy in single vascular endothelial growth factor-A isoform-producing tumorsGillian M Tozer, Simon Akerman, Neil A Cross, et al.
American Journal of Hematology|March 27, 2015
Perioperative use of iloprost in cardiac surgery patients diagnosed with heparin-induced thrombocytopenia-reactive antibodies or with true HIT (HIT-reactive antibodies plus thrombocytopenia): An 11-year experienceGeorge Palatianos, Alkiviadis Michalis, Petros Alivizatos, et al.
Pageof 3